uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed

Dutch Group Gets $450m Upfront For Gene Therapy

 
• By Kevin Grogan

Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.

Genetic breakthrough and medical gene therapy treatment discovery concept as a dart hitting a target by breaking a double helix representing genes as a 3D illustration.
CSL hopes hemophilia B gene therapy will hit the target • Source: Shutterstock

More from Gene Therapies

More from Advanced Therapies